As GLP-1 receptor agonists move rapidly from adult obesity clinics into pediatric practice, a critical question has been left largely unanswered: what happens to the nutritional status of growing children and adolescents whose appetite is pharmacologically suppressed for months or years? A large real-world analysis now provides the first substantial dataset on this gap, and the findings raise meaningful concern.
Drawing from Inovalon administrative claims covering more than 100 million patients, investigators identified 2,031 GLP-1RA users between ages 10 and 17 with no prior nutritional deficiency diagnosis and tracked them for up to one year after treatment initiation. Within that window, 16.88% received a diagnosis of at least one nutritional deficiency or related complication. Vitamin D deficiency was by far the most common, affecting 12.4% of the cohort, followed by nutritional anemia (1.55%) and iron-deficiency anemia (1.44%). Liraglutide accounted for 78.6% of prescriptions, with semaglutide representing only 9.1% — a distribution likely to shift substantially as semaglutide's pediatric approvals expand. Notably, patients who did receive nutrition therapy or counseling (NT/C) showed higher detected rates of deficiency, suggesting surveillance rather than causation was at work.
The most striking finding may not be the deficiency rates themselves, but the glaring underutilization of nutritional support: only 23.3% of patients had an NT/C visit within 180 days of starting a GLP-1RA, with a mean lag of 149 days before the first consultation. For adolescents in peak bone-accrual and growth phases, even transient micronutrient deficits — particularly vitamin D, iron, and B12 — carry disproportionate long-term consequences that may not manifest clinically for years. This study is observational and claims-based, meaning under-diagnosis is probable and causality cannot be established. Still, the scale of the cohort and the consistency of the vitamin D signal reinforce what nutritional science would predict: caloric restriction plus appetite suppression in developing bodies warrants structured, proactive dietary monitoring — a standard that current practice is clearly not meeting.
